865-405-1000 ext. 827

The U.S. Food and Drug Administration has approved the single-tablet HIV treatment regimen Odefsey, which includes a new, safer version of tenofovir.  The tablet is an updated version of Complera, swapping tenofovir alafenamide, or TAF, for tenofovir disoproxil fumarate, or TDF.

Research has shown that TAF is safer to the bones and kidneys than TDF and suppresses HIV just as well. TAF more efficiently enters cells, requiring a dose one tenth that of TDF, and leads to 90 percent less drug in the bloodstream where it may cause toxicities.

Read more about this treatment news here: https://www.poz.com/article/fda-approves-gileads-hiv-tablet-odefsey-updated-version-complera